2024 Market Report by Kings Research “Biologics CDMO Market Size, Share and Ranking, Overall Sales and Demand Forecast 2024-2031″ provides an extensive examination of Biologics CDMO Market attributes, size assessments, and growth projections through segmentation, regional analyses, and country-specific insights, alongside a scrutiny of the competitive landscape, player market shares, and essential business strategies.
Biologics CDMO Market Size was valued at USD 17.26 billion in 2023 and is projected to grow from USD 18.81 billion in 2024 to USD 34.64 billion by 2031, exhibiting a CAGR of 9.12% during the forecast period.
Stay Ahead with Exclusive Insights @ https://www.kingsresearch.com/biologics-cdmo-market-1995
List of Key Companies in Biologics CDMO Market:
- Abzena
- Boehringer Ingelheim International GmbH
- AGC Biologics
- Samsung
- Eurofins Scientific
- WuXi Biologics
- Almac Group
- Lonza
- Curia Global, Inc.
- Siegfried Holding AG
- Thermo Fisher Scientific Inc.
- Rentschler Biopharma SE
- Catalent, Inc.
- Recipharm AB
- FUJIFILM
Market Definition
The market refers to the global industry of outsourcing partners that provide development and manufacturing services for biologic drugs. This market encompasses a broad range of capabilities, including cell line development, process optimization, analytical testing, clinical and commercial-scale production, and fill-finish operations.
Market Dynamics:
Drivers of Market Growth:
Rising Prevalence of Chronic Diseases: The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune disorders is significantly boosting thedemand for biologic therapies. These complex treatments require specialized manufacturing capabilities, positioning CDMOs as pivotal players in the biopharmaceutical supply chain.
Advancements in Biomanufacturing Technologies: Innovations such as single-use bioreactors, continuous manufacturing processes, and the integration of artificial intelligence (AI) and machine learning are enhancing the efficiency and scalability of biologic production. These technological advancements enable CDMOs to meet the growing demand for high-quality biologics while optimizing operational costs .
Challenges Facing the Biologics CDMO Market
Despite the positive growth trajectory, the biologics CDMO market faces several challenges:
Capacity Constraints: The rapid growth of the biologics market has led to capacity constraints, with some CDMOs struggling to keep up with demand. This has resulted in longer lead times and, in some cases, a shortage of available manufacturing slots. CDMOs must invest in expanding their capacity to meet the growing needs of the industry .
Complexity of Biologics Manufacturing: Biologics manufacturing is inherently complex, requiring stringent control over production processes to ensure product consistency and quality. The variability of biological systems adds another layer of complexity, making it challenging for CDMOs to maintain high standards across different projects .
Talent Shortage: The specialized nature of biologics manufacturing requires a highly skilled workforce, particularly in areas such as process development, quality control, and regulatory affairs. However, there is a shortage of talent in these critical areas, making it difficult for CDMOs to attract and retain the expertise needed to drive their operations .
Strategic Developments and Investments:
Fujifilm’s Expansion in North Carolina: Fujifilm announced a $1.2 billion investment to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina. This expansion aims to increase cell culture production to 750,000 liters, positioning Fujifilm to compete more effectively with major industry players such as Lonza, WuXi Biologics, and Samsung Biologics .
Samsung Biologics’ Strategic Partnerships: Samsung Biologics has secured partnerships with leading pharmaceutical companies, including Pfizer, GlaxoSmithKline, and Eli Lilly. These collaborations focus on the manufacturing of monoclonal antibodies, bispecific antibodies, and mRNA vaccines, underscoring Samsung Biologics’ capabilities in large-scale biologics production .
Conclusion
The biologics CDMO market is poised for significant growth, driven by technological advancements, strategic outsourcing, and expanding global demand for biologic therapies. While challenges such as capacity constraints and talent shortages persist, the industry’s resilience and adaptability continue to foster innovation and investment.
About us
At the core of our mission, we strive to drive revenue impact for our clients through exceptional research strategies. With a focus on exclusivity, innovation, and real-time insights, we provide accurate, reliable, and actionable market research data. This empowers our clients to seize opportunities, navigate risks, optimize their strategies effectively, and build the businesses of tomorrow.
Contact us:
Kings Research
Website: https://www.kingsresearch.com
E-mail: [email protected]
Phone: (+1) 888 328 2189
